生物制剂及小分子靶向药物治疗CTD-ILD

Biological agents therapies for connective tissue disease associated interstitial lung disease

间质性肺病(ILD)是影响结缔组织疾病(CTD)预后,甚至导致CTD患者死亡的重要原因之一,结缔组织病相关间质性肺疾病(CTD-ILD)的治疗尚无统一的临床指导策略。近年来在某些激素联合免疫抑制剂治疗无效的CTD-ILD中,生物制剂成为一种有效的治疗方法,但是也有研究发现在应用生物制剂治疗过程中会导致ILD的发生。这篇综述强调治疗CTD-ILD患者时所面临的挑战,并总结了现有的生物制剂治疗CTD-ILD的证据及治疗过程中可能存在的风险。

Interstitial lung disease(ILD)is one of the important causes that affects the prognosis of connective tissue disease(CTD)and might be lethal.There is no unified clinical guidance strategy for the treatment of CTD associated ILD(CTD-ILD).In recent years,biological agents have become an effective treatment for CTD-ILD patients who are refractory to corticosteroids combined with immunosuppressants,but some studies have found that the use of biological agents might lead to ILD.This review highlights the challenges faced when treating patients with CTD-ILD,summarizes the evidence of existing biological agents in the treatment of CTD-ILD and the possible risks.